Abstracts tagged "Medicare"

Abstract Number: 1255 • 2016 ACR/ARHP Annual Meeting
Medicare Part B Utilization By Rheumatology Health Care Providers As Related to Population Demographics from 2013
Sreelakshmi Panginikkod¹, David T Liss², Venu Pararath Gopalakrishnan¹, Pratyusha Bollimunta¹, Andriy Havrylyan¹, Farah Faridi¹ and Manish Jain³, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Northwestern University, Chicago, IL, ³Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: In 2015, the Center for Medicare and Medicaid Services released claims data on payments to over 950,000 health care providers paid through Medicare Part…
Abstract Number: 925 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound (MSK-US): Innovation or Overutilization?
Gurjit S. Kaeley¹, Dale Kraemer², Carmen Smotherman³ and Sunita Dodani⁴, ¹Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ²Center for Health Equity and Quality Research, Department of Neurology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ³Center for Health Equity and Quality Research,, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ⁴Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: MSK-US use has risen in the USA with recent disturbing findings suggesting greater utilization of interventional ultrasound by non-noradiologists compared to Radiologists. (1) This…
Abstract Number: 1268 • 2015 ACR/ARHP Annual Meeting
Utilization of Viscosupplementation: 2011 – 2013
Gurjit S. Kaeley¹, Myint Thway¹ and Sunita Dodani², ¹Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ²Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Viscosupplementation (VS) is approved in the USA as an option for knee osteoarthritis (OA) pain. Recent American Academy of Orthopedic Surgeons (AAOS) guidelines have…
Abstract Number: 1910 • 2014 ACR/ARHP Annual Meeting
Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics
Huifeng Yun¹, Fenglong Xie², Lang Chen³, James Lewis⁴ and Jeffrey R. Curtis⁵, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Healthcare providers have been alerted to the potential drug hypersensitivity reactions (HSRs, an adverse drug reaction that are uncommon but may be severe and…
Abstract Number: 1849 • 2014 ACR/ARHP Annual Meeting
Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴ and Jeffrey R. Curtis⁷, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose The introduction of biologics has greatly changed the treatment of psoriatic arthritis (PsA) and psoriasis (PsO). However, there are concerns regarding the risk of…
Abstract Number: 1070 • 2014 ACR/ARHP Annual Meeting
Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non–Hodgkin′s Lymphoma
Pratibha Nayak¹, Zaki Abou Zahr², Ruili Luo³, Linda Elting³ and Maria E. Suarez-Almazor⁴, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Rheumatology, Baylor College of Medicine, Houston, TX, ³The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Patients with rheumatoid arthritis (RA) have greater risk of non-Hodgkin lymphoma (NHL) than the general population. A previous two-center study suggested that the rates…
Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Pratibha Nayak¹, Ruili Luo², Linda Elting² and Maria E. Suarez-Almazor³, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…
Abstract Number: 2338 • 2013 ACR/ARHP Annual Meeting
Biologic Switching Rates Among Patients With Rheumatoid Arthritis
L Rosenblatt¹, F Lobo¹, P Cockrum², L Wang³, E Alemao², O Baser⁴ and H Yuce⁵, ¹Bristol-Myers Squibb, Plainsboro, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³STATinMED Research, Dallas, TX, ⁴STATinMED Research and University of Michigan, Ann Arbor, MI, ⁵New York City College of Technology (CUNY), Brooklyn, NJ
Background/Purpose: Treatment guidelines for the management of RA recommend sequential use of biologic therapies, and the majority of patients switch from one anti-TNF agent to…
Abstract Number: 1053 • 2013 ACR/ARHP Annual Meeting
Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids…
Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang³, Lang Chen⁴, Huifeng Yun⁵, Michael H. Schiff⁶, Timothy Beukelman⁷ and Seth Ginsberg⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Creaky Joints, New York, NY
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…
Abstract Number: 1048 • 2013 ACR/ARHP Annual Meeting
Generalizability Of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants’ Vs. Non-Participants’ Characteristics
Jeffrey R. Curtis¹, Lang Chen², Huifeng Yun³, Leslie R. Harrold⁴, Jeffrey D. Greenberg⁵ and Joel M. Kremer⁶, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Observational registries provide a valuable complement to clinical trials yet might suffer from limited generalizability referent to the desired population of interest. We compared…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
Abstract Number: 204 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population
E Alemao¹, L Wang², G Lltalien¹, O Baser³, H Yuce⁴ and M Hochberg⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²STATinMED Research, Dallas, TX, ³STATinMED Research and University of Michigan, Ann Arbor, MI, ⁴New York City College of Technology (CUNY), Brooklyn, NJ, ⁵University of Maryland, Baltimore, MD
Background/Purpose: RA-related hospitalization and surgery (e.g. total joint arthroplasty [TJA]) are important long-term outcomes in RA. While advances in treatment for RA have resulted in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].